Skip to main content
SpringerLink
Log in

PERSEPHONE trial shows 6-month trastuzumab has less toxicity

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. American Society of Clinical Oncology

References

  1. Earl HM et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Internet Document : 4 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_217191.html.

  2. ASCO. Shorter Trastuzumab Treatment for HER2+ Breast Cancer Can Be as Effective, With Fewer Cardiac Side Effects. Internet Document : 16 May 2018. Available from: URL: https://www.asco.org/about-asco/press-center/news-releases/shorter-trastuzumab-treatment-her2-breast-cancer-can-be.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PERSEPHONE trial shows 6-month trastuzumab has less toxicity. Reactions Weekly 1703, 6 (2018). https://doi.org/10.1007/s40278-018-46381-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-46381-x

Search

Navigation